Literature DB >> 3264830

Distribution of beta-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus.

M L Joly-Guillo1, E Vallée, E Bergogne-Bérézin, A Philippon.   

Abstract

One hundred clinical strains of Acinetobacter calcoaceticus isolated from 1981 to 1986 were screened for enzymatic resistance to beta-lactam antibiotics. Fourteen beta-lactam antibiotics were tested and four phenotypes were defined on the basis of enzymatic resistance and of susceptibility to the following beta-lactams: ticarcillin, piperacillin, cefotaxime, and ceftazidime. The resistance of A. calcoaceticus to beta-lactam antibiotics was predominantly due to beta-lactamases, which were produced by 81% of the strains. In most (71%) of the beta-lactamase producing strains, a penicillinase of the TEM type was observed; in 9% of the strains, all isolated since 1985, a CARB-type penicillinase with a pI 6.3 was observed. The presence of a cephalosporinase type enzyme was detected in acinetobacter strains isolated since 1981 and its incidence increased in 1986. Multiple beta-lactamases (penicillinase plus cephalosporinase) were observed in 32% of the strains.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264830     DOI: 10.1093/jac/22.5.597

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  Integron- and carbenicillinase-mediated reduced susceptibility to amoxicillin-clavulanic acid in isolates of multidrug-resistant Salmonella enterica serotype typhimurium DT104 from French patients.

Authors:  L Poirel; M Guibert; S Bellais; T Naas; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Epidemiology of extended spectrum beta-lactamases.

Authors:  A Philippon; S Ben Redjeb; G Fournier; A Ben Hassen
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

3.  SCO-1, a novel plasmid-mediated class A beta-lactamase with carbenicillinase characteristics from Escherichia coli.

Authors:  C C Papagiannitsis; A Loli; L S Tzouvelekis; E Tzelepi; G Arlet; V Miriagou
Journal:  Antimicrob Agents Chemother       Date:  2007-03-12       Impact factor: 5.191

4.  The increasing role of Acinetobacter species as nosocomial pathogens.

Authors:  Eugénie Bergogne-Bérézin
Journal:  Curr Infect Dis Rep       Date:  2007-10       Impact factor: 3.725

Review 5.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

6.  Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study).

Authors:  V Jarlier; T Fosse; A Philippon
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

7.  Antimicrobial susceptibility of Acinetobacter species.

Authors:  H Seifert; R Baginski; A Schulze; G Pulverer
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

8.  Carbapenem resistance mediated by beta-lactamases in clinical isolates of Acinetobacter baumannii in Spain.

Authors:  S López-Hernández; T Alarcón; M López-Brea
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

9.  Characterization of the chromosomal cephalosporinases produced by Acinetobacter lwoffii and Acinetobacter baumannii clinical isolates.

Authors:  M Perilli; A Felici; A Oratore; G Cornaglia; G Bonfiglio; G M Rossolini; G Amicosante
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

10.  In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii.

Authors:  J Vila; A Marcos; F Marco; S Abdalla; Y Vergara; R Reig; R Gomez-Lus; T Jimenez de Anta
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.